Ken Griffin Catalyst Biosciences, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2023

Nov 14, 2023
BUY
$0.33 - $0.65 $363 - $715
1,100 New
1,100 $0
Q1 2023

May 15, 2023
SELL
$0.19 - $0.64 $779 - $2,624
-4,100 Reduced 41.84%
5,700 $1,000
Q4 2022

Feb 14, 2023
SELL
$0.49 - $0.57 $58,702 - $68,286
-119,800 Reduced 92.44%
9,800 $5,000
Q3 2022

Nov 14, 2022
SELL
$0.49 - $1.95 $33,614 - $133,770
-68,600 Reduced 34.61%
129,600 $65,000

Others Institutions Holding CBIO

# of Institutions
1
Shares Held
215
Call Options Held
0
Put Options Held
0
View Full List

About CATALYST BIOSCIENCES, INC.

CBIO Quotes by TradingView
  • Ticker CBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,477,100
  • Description
  • Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB ...
More about CBIO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email